+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

KOL Perspectives: BTK Inhibitors in RA

  • PDF Icon

    Drug Pipelines

  • 26 Pages
  • August 2018
  • Region: Global
  • GlobalData
  • ID: 4701805
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.


This KOL Insight briefing focuses on KOLs views of BTK Inhibitors in RA.

Questions topics -
  • Awareness and potential of BTK inhibitors in RA

  • Perceptions of BMS-986142’s Phase IItrial design

  • Impact of poseltinib discontinuation on existing perception of BTK inhibitors in RA

Key Highlights
  • Of the named BTK inhibitors, KOLs demonstrated the greatest awareness of BMS-986142, despite its lack of Phase II data

  • KOLs were divided over BMS-986142’s ability to achieve ACR70 by Week 12 in a refractory patient population

  • For the majority of KOLs, poseltinib’s discontinuation had little to no impact on their existing perception of BTK inhibitors in RA.

  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our RA key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs -
  • 5 Europe-based & 5 N. America-based

  • Interviews performed during Q2 2018

KOL data is analyzed to produce -
  • Charts summarizing KOL opinions

  • Chart call-outs of key information & details

  • KOL quotes

  • Summary of KOL reporting trends

  • Insight from Sociable Pharma's analysts

Reasons to Buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on BTK Inhibitors in RA

  • Includes insight & recommendations from our disease-specific healthcare analysts

  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of RA

  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Table of Contents

  • Executive Summary

  • Background

  • Research Panel Composition

  • Results & Implications

  • Appendix



Companies Mentioned

A selection of companies mentioned in this report includes:

  • BMS

  • Lilly

  • Roche

  • Merck

  • AbbVie